Objective:To investigate on the curative effects of Azelastine Nasal Spray combined with Yupinfeng Powder in the treatment of patients with moderate and severe allergic rhinitis(AR) and explore whether C-reactive protein(CRP) can provide references for the treatment of moderate and severe AR.Method:A total of 168 patients with moderate and severe AR admitted to our hospital from November 2012 to December 2014 were collected,and they were divided into three groups according to the different treatment methods,56 cases in each group.The combined treatment group was given Azelastine Nasal Spray combined with Yupinfeng Powder for treatment,the Azelastine Nasal Spray group was given Azelastine Nasal Spray for treatment,and the control group was given Loratadine and Fluticasone Propionate Nasal Spray for treatment.The curative effects among the three groups were compared,the serum CRP were examined before the treatment and 8 weeks after the treatment.Result:The total effective rate of the combined treatment group was 96.43%,which was significantly higher than 69.64% of the Azelastine Nasal Spray group and 66.07% of the control group,the differences were statistically significant (P<0.05).The recurrence rate of the combined treatment group was 3.70%,which was significantly lower than 20.51% of the Azelastine Nasal Spray group and 27.03% of the control group,the differences were statistically significant(P<0.01).The serum CRP of the three groups after treatment were significantly lower than those of before treatment,the differences were statistically significant(P<0.01).The serum CRP of the combined treatment group was significantly lower than the Azelastine Nasal Spray group and the control group,and the serum CRP of Azelastine Nasal Spray group was significantly lower than the control group,the differences were statistically significant(P<0.05).Conclusion:Combined treatment of Azelastine Nasal Spray and Yupinfeng Powder has more obvious curative effects and lower recurrence rate,it better than single medication in the treatment of patients with moderate and severe AR.CRP can be used as a clinical reference.%目的：探讨氮卓斯汀鼻喷剂联合玉屏风散治疗中-重度变应性鼻炎（AR）的疗效及探索 C反应蛋白（CRP）是否可为中-重度AR疗效提供参考依据。方法：收集本院门诊2012年11月-2014年12月收治的中-重度过敏性鼻炎患者168例，按照治疗方法的不同将其分为三组，联合治疗组给予盐酸氮卓斯汀鼻喷剂联合玉屏风散治疗，盐酸氮卓斯汀组给予盐酸氮卓斯汀鼻喷剂治疗，对照组给予氯雷他定与丙酸氟替卡松鼻喷雾剂治疗，每组56例。在治疗前和停止治疗后8周检查三组患者的疗效，同时检测患者的血清CRP值。结果：联合治疗组的总有效率为96.43%，明显高于盐酸氮卓斯汀组的69.64%和对照组的66.07%，差异均有统计学意义（P<0.05）。联合治疗组的复发率为3.70%，明显低于盐酸氮卓斯丁组的20.51%和对照组的27.03%，差异均有统计学意义（P<0.01）。三组患者治疗后的血清CRP较治疗前均明显下降，差异均有统计学意义（P<0.01）。联合治疗组的血清CRP明显低于盐酸氮卓斯汀组和对照组，而盐酸氮卓斯汀组的血清CRP明显低于对照组，差异均有统计学意义（P<0.05）。结论：盐酸氮卓斯汀鼻喷剂联合玉屏风散治疗中-重度过敏性鼻炎的疗效明显，复发率低，较单独使用效果更好， CRP可以作为临床参考依据之一。
展开▼
